Table 3.
The diagnostic performance of DT 5.0 model and the seven TAAbs in early and late stage LC.
| TAAbs | AUC (95% CI) | P | Sensitivity (%) | Specificity (%) | YI | PPV (%) | NPV (%) | Accuracy (%) |
|---|---|---|---|---|---|---|---|---|
| Early stage (I + II; N = 72) | ||||||||
| TP53 | 0.840 (0.782–0.898) | 0.000 | 48.6 | 92.7 | 0.413 | 86.89 | 64.33 | 70.64 |
| NPM1 | 0.837 (0.778–0.897) | 0.000 | 48.6 | 94.0 | 0.426 | 89.01 | 64.65 | 71.31 |
| GNA11 | 0.733 (0.672–0.793) | 0.000 | 26.4 | 95.3 | 0.217 | 84.97 | 56.43 | 60.86 |
| HIST1H3B | 0.567 (0.484–0.650) | 0.078 | 13.9 | 95.3 | 0.092 | 74.85 | 52.54 | 54.61 |
| FGFR2 | 0.639 (0.558–0.719) | 0.000 | 15.3 | 94.0 | 0.093 | 71.80 | 52.60 | 54.64 |
| TSC1 | 0.749 (0.683–0.816) | 0.000 | 18.1 | 92.0 | 0.101 | 69.30 | 52.89 | 55.03 |
| PIK3CA | 0.668 (0.592–0.744) | 0.000 | 15.3 | 93.3 | 0.086 | 69.62 | 52.42 | 54.31 |
| DT C5.0 | 0.886 (0.845–0.926) | 0.000 | 94.4 | 82.7 | 0.771 | 84.49 | 93.70 | 88.56 |
| Late stage (III + IV; N = 141) | ||||||||
| TP53 | 0.710 (0.651–0.769) | 0.000 | 35.5 | 92.7 | 0.281 | 82.86 | 58.95 | 64.06 |
| NPM1 | 0.707 (0.650–0.764) | 0.000 | 27.0 | 94.0 | 0.210 | 81.79 | 56.27 | 60.48 |
| GNA11 | 0.727 (0.679–0.774) | 0.000 | 19.1 | 95.3 | 0.145 | 80.41 | 54.11 | 57.24 |
| HIST1H3B | 0.565 (0.506–0.624) | 0.027 | 9.2 | 95.3 | 0.046 | 66.39 | 51.22 | 52.28 |
| FGFR2 | 0.509 (0.448–0.571) | 0.750 | 7.8 | 91.0 | −0.012 | 46.43 | 49.67 | 49.40 |
| TSC1 | 0.641 (0.582–0.701) | 0.000 | 9.2 | 92.0 | 0.012 | 53.54 | 50.33 | 50.61 |
| PIK3CA | 0.576 (0.516–0.636) | 0.010 | 14.9 | 90.0 | 0.049 | 59.82 | 51.40 | 52.45 |
| DT C5.0 | 0.864 (0.826–0.902) | 0.000 | 90.1 | 82.7 | 0.727 | 83.86 | 89.28 | 86.37 |
AUC, area under the receiver operating characteristic curve; CI, confidence interval; DT C5.0, Decision Tree C5.0; LC, lung cancer; NPV, negative predictive value; PPV, positive predictive value; TAAbs, autoantibodies to tumor-associated antigens; YI, Youden's Index.